ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1045

Myocardial Involvement in SSc: Key Role of Lin-gp38+ Stromal Cells in the Onset of Fibrosis and Defects of the Conduction System

Mara Stellato1, Michal Rudnik 2, Florian Renoux 3, Przemyslaw Blyszczuk 4, Elena Osto 5, Matthias Dewenter 6, Petra Seebeck 7, Elena Pachera 2, Oliver Distler 8 and Gabriela Kania 4, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Zurich, Switzerland, 3Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, 4Centre of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Institute of Clinical Chemistry, University Hospital Zurich, Switzerland, Zurich, Zurich, Switzerland, 6Department of Molecular Cardiology and Epigenetics, University Hospital, Heidelberg, Germany, Heidelberg, Germany, 7Zurich integrative Rodent Physiology, University of Zurich, Switzerland, Zurich, Switzerland, 8Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cardiac fibrosis, Conduction system, Fra-2, Stromal cells and SSc

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiac fibrosis is a known complication of SSc, associated with increased mortality. During fibrogenesis, fibroblasts differentiate into myofibroblasts and secrete excessive extracellular matrix proteins. Here, we aim to identify the role of a specific fibroblast subset in fibrogenesis and defects of the cardiac electrophysiology in the Fra2 transgenic (tg) mouse model.

Methods: Cardiac function of Fra2 tg and Rag2-/- Fra2 tg mice was assessed by echocardiography, ECG and radiotelemetry. Hearts were analysed by immunohistochemistry (IHC) and IF. The myocardial fibroblast subset represented by stromal (Ter119–CD45–CD31–, hereafter Lin–) gp38+ cells, was sorted and cultured. The phenotype was evaluated by qPCR, α-smooth muscle actin (αSMA) and stress fibre IF, secreted collagens and contraction assay. Proliferation and apoptosis were measured by BrdU incorporation and Caspase 3/7 activity.

Results: Fra2 tg mice displayed increased ejection fraction (p=0.02) and fractional shortening (p=0.02) with decreased left ventricle end-diameter and end-volume in systole (p=0.006, p=0.008) and in diastole (p=0.007, p=0.008) in echocardiography. ECG in conscious mice revealed lower heart rate (HR) (WT 741 ± 33 BPM, tg 644 ± 37 BPM, p< 0.0001) and prolonged QRS, ST and QTc parameters (p=0.001, p=0.01, p=0.01), which may predispose to arrhythmias. Continuous ECG measured by radiotelemetry showed the presence of atrioventricular (AV) blocks that correlated with phenotype severity score (R=0.9, p=0.02). Fibrosis might be responsible for these changes by separating myocardial bundles, causing improper conduction. Indeed, the myocardium of Fra2 tg mice uncovered mild inflammation and interstitial fibrosis with higher expression of collagen- (p=0.03, n=7) and periostin-expressing cells (p=0.001, n=7), increased number of αSMA+ myofibroblasts as well as Lin-gp38+ cells compared to WT mice (1.4% ± 1.4, n=15 and Fra-2 tg: 6% ± 4.5, n=14, p=0.001). Importantly, the majority of myocardial Fra-2 tg gp38+ cells co-expressed αSMA, collagen, ADAM12 and periostin, indicating a myofibroblast-like phenotype. Finally, gp38 expression correlated with collagen deposition (R=0.9, p< 0.0001) measured by Sirius Red staining. In vitro, sorted Lin-gp38+ cells isolated from Fra2 tg mice showed increased αSMA total protein and αSMA fibres that co-localized with stress fibres, resulting in a faster and stronger contraction capability of Fra2 tg cells (p< 0.0001, n=3). Proliferation of Fra2 tg cells was increased compared to WT cells (p=0.007, n=5), while apoptosis was unchanged (p=0.335, n=5). Rag2-/-Fra2 tg mice showed no myocardial fibrosis or Lin-gp38+ cell expansion. ECG parameters of Rag2-/-Fra2 tg mice did not differ from control mice, indicating that inflammation is necessary to acquire the Fra2-driven fibrotic phenotype and defects in the conduction system.

Conclusion: Fra2 overexpression and inflammation drive the differentiation of fibroblasts into myofibroblasts, leading to cardiac fibrosis and defects of the conduction system. This mechanism might be a therapeutic target for SSc patients with disorders of the cardiac conduction system.


Disclosure: M. Stellato, None; M. Rudnik, None; F. Renoux, None; P. Blyszczuk, None; E. Osto, None; M. Dewenter, None; P. Seebeck, None; E. Pachera, None; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5; G. Kania, Bayer, 2, Actelion, 8, Boehringer Ingelheim, 8.

To cite this abstract in AMA style:

Stellato M, Rudnik M, Renoux F, Blyszczuk P, Osto E, Dewenter M, Seebeck P, Pachera E, Distler O, Kania G. Myocardial Involvement in SSc: Key Role of Lin-gp38+ Stromal Cells in the Onset of Fibrosis and Defects of the Conduction System [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/myocardial-involvement-in-ssc-key-role-of-lin-gp38-stromal-cells-in-the-onset-of-fibrosis-and-defects-of-the-conduction-system/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myocardial-involvement-in-ssc-key-role-of-lin-gp38-stromal-cells-in-the-onset-of-fibrosis-and-defects-of-the-conduction-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology